REGNITE® (gabapentin enacarbil) Extended Release Tablets received marketing approval in Japan for the treatment of moderate-to-severe primary restless legs syndrome (RLS) in January 2012. Astellas Pharma Inc. holds exclusive rights to develop and commercialize gabapentin enacarbil in Japan. XenoPort is entitled to receive percentage-based high-teen royalties on net sales of REGNITE in Japan.